For patients on Hydroxychloroquine or Chloroquine
The Royal College of Ophthalmologists recommends a baseline assessment and annual screening for retinal toxicity for patients on long-term therapy of Hydroxychloroquine and Chloroquine. This service allows for the community retinal screening of patients within optical practice.
The LOCSU pathway and clinical management guidelines offer an integrated service delivery model with data collection in primary care and virtual review by a consultant ophthalmologist. Aligning to the RCOphth guidelines, this allows for patients to be seen within the community in a consultant-led service. The service aims to identify patients at risk of vision loss through screening.
LOCSU has developed a comprehensive Clinical Service Pathways Framework incorporating Medical Retina Monitoring (Hydroxychloroquine), Medical Retina Monitoring pathway diagram and Medical Retina Monitoring Clinical Management Guidelines.
LOCs can access the framework diagrams, guidelines and support documents by logging in to the members area at the bottom of page.
NHS Commissioners can access these documents by contacting their Local Optical Committee.
Other Useful Documents:
- Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening – Royal College of Ophthalmologists guidance
- Patient Leaflet – Eye screening for patients taking hydroxychloroquine – Macular Society Royal College of Ophthalmologists